These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 35852795)

  • 1. Upfront Biology-Guided Therapy in Diffuse Intrinsic Pontine Glioma: Therapeutic, Molecular, and Biomarker Outcomes from PNOC003.
    Kline C; Jain P; Kilburn L; Bonner ER; Gupta N; Crawford JR; Banerjee A; Packer RJ; Villanueva-Meyer J; Luks T; Zhang Y; Kambhampati M; Zhang J; Yadavilli S; Zhang B; Gaonkar KS; Rokita JL; Kraya A; Kuhn J; Liang W; Byron S; Berens M; Molinaro A; Prados M; Resnick A; Waszak SM; Nazarian J; Mueller S
    Clin Cancer Res; 2022 Sep; 28(18):3965-3978. PubMed ID: 35852795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pilot precision medicine trial for children with diffuse intrinsic pontine glioma-PNOC003: A report from the Pacific Pediatric Neuro-Oncology Consortium.
    Mueller S; Jain P; Liang WS; Kilburn L; Kline C; Gupta N; Panditharatna E; Magge SN; Zhang B; Zhu Y; Crawford JR; Banerjee A; Nazemi K; Packer RJ; Petritsch CK; Truffaux N; Roos A; Nasser S; Phillips JJ; Solomon D; Molinaro A; Waanders AJ; Byron SA; Berens ME; Kuhn J; Nazarian J; Prados M; Resnick AC
    Int J Cancer; 2019 Oct; 145(7):1889-1901. PubMed ID: 30861105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adult diffuse intrinsic pontine glioma: clinical, radiological, pathological, molecular features, and treatments of 96 patients.
    Wang Y; Pan C; Xie M; Zuo P; Li X; Gu G; Li T; Jiang Z; Wu Z; Zhang J; Zhang L
    J Neurosurg; 2022 Dec; 137(6):1628-1638. PubMed ID: 35395636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of patients ≥10 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG/DMG Registry.
    Erker C; Lane A; Chaney B; Leary S; Minturn JE; Bartels U; Packer RJ; Dorris K; Gottardo NG; Warren KE; Broniscer A; Kieran MW; Zhu X; White P; Dexheimer PJ; Black K; Asher A; DeWire M; Hansford JR; Gururangan S; Nazarian J; Ziegler DS; Sandler E; Bartlett A; Goldman S; Shih CS; Hassall T; Dholaria H; Bandopadhayay P; Samson Y; Monje M; Fisher PG; Dodgshun A; Parkin S; Chintagumpala M; Tsui K; Gass D; Larouche V; Broxson E; Garcia Lombardi M; Wang SS; Ma J; Hawkins C; Hamideh D; Wagner L; Koschmann C; Fuller C; Drissi R; Jones BV; Leach J; Fouladi M
    Neuro Oncol; 2022 Jan; 24(1):141-152. PubMed ID: 34114629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spatial genomic heterogeneity in diffuse intrinsic pontine and midline high-grade glioma: implications for diagnostic biopsy and targeted therapeutics.
    Hoffman LM; DeWire M; Ryall S; Buczkowicz P; Leach J; Miles L; Ramani A; Brudno M; Kumar SS; Drissi R; Dexheimer P; Salloum R; Chow L; Hummel T; Stevenson C; Lu QR; Jones B; Witte D; Aronow B; Hawkins CE; Fouladi M
    Acta Neuropathol Commun; 2016 Jan; 4():1. PubMed ID: 26727948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medulloblastoma therapy generates risk of a poorly-prognostic H3 wild-type subgroup of diffuse intrinsic pontine glioma: a report from the International DIPG Registry.
    Gits HC; Anderson M; Stallard S; Pratt D; Zon B; Howell C; Kumar-Sinha C; Vats P; Kasaian K; Polan D; Matuszak M; Spratt DE; Leonard M; Qin T; Zhao L; Leach J; Chaney B; Escorza NY; Hendershot J; Jones B; Fuller C; Leary S; Bartels U; Bouffet E; Yock TI; Robertson P; Mody R; Venneti S; Chinnaiyan AM; Fouladi M; Gottardo NG; Koschmann C
    Acta Neuropathol Commun; 2018 Jul; 6(1):67. PubMed ID: 30049282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developing H3K27M mutant selective radiosensitization strategies in diffuse intrinsic pontine glioma.
    Parsels LA; Wahl DR; Koschmann C; Morgan MA; Zhang Q
    Neoplasia; 2023 Mar; 37():100881. PubMed ID: 36724689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversal of cancer gene expression identifies repurposed drugs for diffuse intrinsic pontine glioma.
    Zhao G; Newbury P; Ishi Y; Chekalin E; Zeng B; Glicksberg BS; Wen A; Paithankar S; Sasaki T; Suri A; Nazarian J; Pacold ME; Brat DJ; Nicolaides T; Chen B; Hashizume R
    Acta Neuropathol Commun; 2022 Oct; 10(1):150. PubMed ID: 36274161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiogenomics of diffuse intrinsic pontine gliomas (DIPGs): correlation of histological and biological characteristics with multimodal MRI features.
    Calmon R; Dangouloff-Ros V; Varlet P; Deroulers C; Philippe C; Debily MA; Castel D; Beccaria K; Blauwblomme T; Grevent D; Levy R; Roux CJ; Purcell Y; Saitovitch A; Zilbovicius M; Dufour C; Puget S; Grill J; Boddaert N
    Eur Radiol; 2021 Dec; 31(12):8913-8924. PubMed ID: 34003354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative multidimensional molecular analyses of pediatric diffuse intrinsic pontine glioma reveals distinct molecular subtypes.
    Saratsis AM; Kambhampati M; Snyder K; Yadavilli S; Devaney JM; Harmon B; Hall J; Raabe EH; An P; Weingart M; Rood BR; Magge SN; MacDonald TJ; Packer RJ; Nazarian J
    Acta Neuropathol; 2014; 127(6):881-95. PubMed ID: 24297113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot radiogenomic study of DIPG reveals distinct subgroups with unique clinical trajectories and therapeutic targets.
    Zhu X; Lazow MA; Schafer A; Bartlett A; Senthil Kumar S; Mishra DK; Dexheimer P; DeWire M; Fuller C; Leach JL; Fouladi M; Drissi R
    Acta Neuropathol Commun; 2021 Jan; 9(1):14. PubMed ID: 33431066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances and Clinical Trials Update in the Treatment of Diffuse Intrinsic Pontine Gliomas.
    Dalle Ore C; Coleman C; Gupta N; Mueller S
    Pediatr Neurosurg; 2023; 58(5):259-266. PubMed ID: 36642062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined Targeting of Mutant p53 and Jumonji Family Histone Demethylase Augments Therapeutic Efficacy of Radiation in H3K27M DIPG.
    Nikolaev A; Fiveash JB; Yang ES
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31940975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tenascin-C expression contributes to pediatric brainstem glioma tumor phenotype and represents a novel biomarker of disease.
    Qi J; Esfahani DR; Huang T; Ozark P; Bartom E; Hashizume R; Bonner ER; An S; Horbinski CM; James CD; Saratsis AM
    Acta Neuropathol Commun; 2019 May; 7(1):75. PubMed ID: 31092287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TP53 Pathway Alterations Drive Radioresistance in Diffuse Intrinsic Pontine Gliomas (DIPG).
    Werbrouck C; Evangelista CCS; Lobón-Iglesias MJ; Barret E; Le Teuff G; Merlevede J; Brusini R; Kergrohen T; Mondini M; Bolle S; Varlet P; Beccaria K; Boddaert N; Puget S; Grill J; Debily MA; Castel D
    Clin Cancer Res; 2019 Nov; 25(22):6788-6800. PubMed ID: 31481512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic targeting of transcriptional elongation in diffuse intrinsic pontine glioma.
    Katagi H; Takata N; Aoi Y; Zhang Y; Rendleman EJ; Blyth GT; Eckerdt FD; Tomita Y; Sasaki T; Saratsis AM; Kondo A; Goldman S; Becher OJ; Smith E; Zou L; Shilatifard A; Hashizume R
    Neuro Oncol; 2021 Aug; 23(8):1348-1359. PubMed ID: 33471107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-time drug testing of paediatric diffuse midline glioma to support clinical decision making: The Zurich DIPG/DMG centre experience.
    Mueller T; Laternser S; Guerreiro Stücklin AS; Gerber NU; Mourabit S; Rizo M; Rushing EJ; Kottke R; Grotzer M; Krayenbühl N; Nazarian J; Mueller S
    Eur J Cancer; 2023 Jan; 178():171-179. PubMed ID: 36455411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Signal Transduction in Diffuse Intrinsic Pontine Glioma.
    Duchatel RJ; Jackson ER; Alvaro F; Nixon B; Hondermarck H; Dun MD
    Proteomics; 2019 Nov; 19(21-22):e1800479. PubMed ID: 31328874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone tail analysis reveals H3K36me2 and H4K16ac as epigenetic signatures of diffuse intrinsic pontine glioma.
    An S; Camarillo JM; Huang TY; Li D; Morris JA; Zoltek MA; Qi J; Behbahani M; Kambhampati M; Kelleher NL; Nazarian J; Thomas PM; Saratsis AM
    J Exp Clin Cancer Res; 2020 Nov; 39(1):261. PubMed ID: 33239043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist.
    Xu C; Liu H; Pirozzi CJ; Chen LH; Greer PK; Diplas BH; Zhang L; Waitkus MS; He Y; Yan H
    Acta Neuropathol Commun; 2021 Nov; 9(1):178. PubMed ID: 34732238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.